LONDON and MONTREAL, April 27, 2017 /CNW/ -- DalCor Pharmaceuticals today announced that senior management will present at the Bloom Burton & Co. Healthcare Investor Conference 2017 on Tuesday, May 2nd at 2:30 pm Eastern Time at the Sheraton Centre Toronto Hotel in Toronto, Canada.
Robert McNeil, Ph.D., chief executive officer and Donald M. Black, M.D., chief medical officer, will provide a corporate overview of the company's business and will be available for one-on-one meetings during the event.
About DalCor Pharmaceuticals
DalCor is developing precision treatments by genetically targeting patients that will derive clinical benefits. By integrating clinical and genetic insights, DalCor intends to deliver superior clinical cardiovascular outcomes. The company's first development program, dalcetrapib, is intended to reduce cardiovascular events in a specific genetic subset of patients.
On March 7, DalCor announced it is ahead of its enrollment schedule with the randomization of over 1,000 patients of the expected 5,000 patients planned for the Phase 3 "dal-GenE" clinical trial, a cardiovascular outcomes study of dalcetrapib in patients with acute coronary syndrome (ACS) and the AA genotype in the ADCY9 gene. Patients have been recruited at 642 hospitals in 30 countries, including the U.S., and on six continents.
DalCor has a worldwide exclusive license for dalcetrapib together with rights to the genetic marker for use with dalcetrapib and is sponsoring the dal-GenE study.
DalCor Pharmaceuticals has offices in Montreal, San Mateo, Calif., Zug, Switzerland and Stockport, U.K. For more information, visit www.dalcorpharma.com
About the Bloom Burton & Co. Healthcare Investor Conference
Bloom Burton & Co. is hosting its sixth annual Healthcare Investor Conference on May 1 and 2, 2017 at the Sheraton Centre Toronto Hotel, Toronto, Canada. The conference aims to showcase approximately sixty of the premier Canadian healthcare companies to its network of investors, who generally join the conference from Canada, the U.S. and Europe. The event attracts investors who are interested in the latest developments in Canadian healthcare companies. Investors will have the opportunity to obtain corporate updates from presenting companies and participate in 1-on-1 meetings with company management.
DalCor Contacts:
Russo Partners
Alexander Fudukidis
(646) 942-5632
[email protected]
SOURCE DalCor Pharmaceuticals
Share this article